Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 401–500 of 914
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Mazzu, Y. Z., Armenia, J., Nandakumar, S., Chakraborty, G., Yoshikawa, Y., Jehane, L. E., Lee, G. M., Atiq, M. O., Khan, N. A., Schultz, N. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12706 · Cited by 51
“…studies have attempted to establish individual biomarkers or gene expression signatures to predict aggressive cases of prostate cancer (Bibikova et al ., 2007; Cuzick et al ., 2011; Glinsky et al ., 2005; Penney et al ., 2011), but these studies were limited by the small number of samples analyzed.”
The Role of Polycomb Group Protein BMI1 in DNA Repair and Genomic Stability
Fitieh, A. M., Locke, A. J., Motamedi, M., & Ismail, I. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062976 · Cited by 47
Li, Z. H., Yin, Y., Du, C., FU, H., WANG, J., & Tian, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1188 · Cited by 41
“High expression levels of USP22 are used to predict the time of recurrence, distant metastasis and treat-ment failure and correlate with poor prognosis in a number of types of tumor (11,17,18).”
RetractedThe wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis
Koziol, J. A., Feng, A. C., Jia, Z., Wang, Y., Goodison, S., McClelland, M., & Mercola, D. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn354 · Cited by 39
Borczuk, A., Toonkel, R. L., & Powell, C. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-076lc · Cited by 53
“In addition, Glinsky and colleagues reported that a gene signature of ‘‘stemness’’ derived from BMI-1–regulated genes in normal stem cells is associated with metastasis and survival in several tumor types, including NSCLC (31).”
BackgroundInfluentialKirby, J., Heath, P. R., Shaw, P. J., & Hamdy, F. C. (2007) · Advances in clinical chemistry · doi:10.1016/s0065-2423(07)44008-2 · Cited by 47
Drier, Y., & Domany, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017795 · Cited by 39
“We did not consider the Oncotype DX recurrence signature [28], which was constructed by carefully picking genes from relevant pathways (and therefore indeed, capture many pathways); the P53 signature [24], BMI1 signature [27] and wound response signature [23,29], each of which was constructed to capture a specific pat…”
BackgroundMethodTanaka, S., Mogushi, K., Yasen, M., Ban, D., Noguchi, N., Irie, T., Kudo, A., Nakamura, N., Tanaka, H., Yamamoto, M., et al. (2011) · Hepatology · doi:10.1002/hep.24536 · Cited by 41
“regarding transcription profiles.(4) Furthermore, such studies should potentially lead to the development of a novel, molecular-targeting therapy of HCC.”
BackgroundshRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis
Meng, X., Wang, Y., Zheng, X., Liu, C., Su, B., Nie, H., Zhao, B.-X., Zhao, X., & Yang, H. Y. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.02.015 · Cited by 39
“Bmi-1 is highly expressed in several ancers, such as lung [2], breast [3], colorectal [4], nasopharyngeal 5], metastatic melanoma [6], and prostate cancers [7].”
BackgroundPeyre, M., Commo, F., Dantas-Barbosa, C., Andreiuolo, F. D. M., Puget, S., Lacroix, L., Drusch, F., Scott, V., Varlet, P., Mauguen, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012932 · Cited by 39
“The common signature at relapse also unveils several genes already described in the death-from-cancer signature [43] Figure 6.”
BackgroundYun, X., Zhang, K., Wang, J., Pangeni, R. P., Yang, L., Bonner, M., Wu, J., Wang, J., Nardi, I. K., Gao, M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0042 · Cited by 39
“A number of studies suggest that elevation of USP22 was involved in tumor progression and highly malignant clinico-biological features, correlates with therapy resistance and poor prognosis (14, 17, 36).”
BackgroundJoaquim Bellmunt, B. (2018) · Biomedicines · doi:10.3390/biomedicines6030085 · Cited by 41
“A genomics approach revealed an 11-gene signature (including BMI1) that consistently displayed a stem-cell-resembling expression profile in distant metastatic lesions of different cancers, including bladder cancers [67].”
BackgroundGenomic Prognostic Models in Early-Stage Lung Cancer
Kratz, J. R., & Jablons, D. M. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.021 · Cited by 38
In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution
Villadsen, R. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_344.x · Cited by 42
“Dissecting the hierarchical models of cellular replacement is important not only for the basic understanding of tissue homeostasis but also for contributing to the rapidly developing field of cancer profiling (6, 7).”
BackgroundUSP22 Promotes NSCLC Tumorigenesis via MDMX Up-Regulation and Subsequent p53 Inhibition
Ding, F., Bao, C., Tian, Y., Xiao, H., Wang, M., Xie, X., Hu, F., & Mei, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010307 · Cited by 40
“resistance in multiple cancers [8].”
Qiu, G., Mao, X., Ma, Y., Gao, X., Wang, Z., Jin, M., Sun, W., Zou, Y., Lin, J., Fu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13646 · Cited by 39
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
O’Hagan, R. C., & Heyer, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408080 · Cited by 45
Büchner, A., Castro, M., Hennig, A., Popp, T., Assmann, G., Stief, C. G., & Zimmermann, W. (2010) · Urology · doi:10.1016/j.urology.2010.03.042 · Cited by 41
Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma
Tang, B., Liang, X., Tang, F., ZHANG, J., Zeng, S., Jin, S., Zhou, L., Kudo, Y., & Qi, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3214 · Cited by 39
“fied 11-gene polycomb/cancer stem cell signature including USP22 (18-20).”
RetractedSiddique, H. R., Parray, A., Tarapore, R. S., Wang, L., Mukhtar, H., Karnes, R. J., Deng, Y., Konety, B. R., & Saleem, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060664 · Cited by 40
“identified BMI1 as one the signature molecules in a broad spectrum of therapy-resistant cancers including CaP [17].”
BackgroundBmi-1 induces radioresistance in MCF-7 mammary carcinoma cells
LIU, Z.-G., LIU, L., XU, L.-H., YI, W., TAO, Y.-L., TU, Z.-W., LI, M.-Z., ZENG, M.-S., & XIA, Y.-F. (2012) · Oncology Reports · doi:10.3892/or.2011.1615 · Cited by 36
“Furthermore, Bmi-1-associated gene expression pathway, which is 11 gene Bmi-1 stem cell signature, is a powerful predictor of a short interval to distant metastasis, highly malignant clinical course of disease progression, and high likehood of therapy failure in multiple types of human cancer (24).”
BackgroundZhang, D., Jiang, F., Wang, X., & Li, G. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14772395226335 · Cited by 40
Zhang, K., Wang, J., Tong, T. R. S.-W., Wu, X., Nelson, R. A., Yuan, Y., Reno, T. A., Liu, Z., Yun, X., Kim, J. Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30769 · Cited by 37
“reported that an 11-gene signature including USP22 mRNA is associated with aggressive growth, metastasis, and therapy resistance in a number of human cancers, including lung cancer.(27) One study showed that knockdown of USP22 decreased cell proliferation in several cancer cell lines, suggesting that USP22 might be a…”
BackgroundThe Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer
Yoo, Y. A., Vatapalli, R. J., Lysy, B., Mok, H., Desouki, M. M., & Abdulkadir, S. A. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy142 · Cited by 37
BMI1 is a therapeutic target in recurrent medulloblastoma
Bakhshinyan, D., Venugopal, C., Adile, A., Garg, N., Manoranjan, B., Hallett, R. M., Wang, X., Mahendram, S., Vora, P., Vijayakumar, T., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0549-9 · Cited by 39
Badodi, S., Pomella, N., Zhang, X., Rosser, G., Whittingham, J., Niklison-Chirou, M. V., Lim, Y. M., Brandner, S., Morrison, G. M., Pollard, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22379-7 · Cited by 49
Oh, D. H., Rigas, D., Cho, A., & Chan, J. Y. (2012) · FEBS Journal · doi:10.1111/febs.12005 · Cited by 45
Reinisch, C., Kandutsch, S., Uthman, A., & Pammer, J. (2006) · PubMed · doi:10.14670/hh-21.1143 · Cited by 41
Usp22 deficiency impairs intestinal epithelial lineage specification in vivo
Kosinsky, R. L., Wegwitz, F., Hellbach, N., Dobbelstein, M., Mansouri, A., Vogel, T., Begus-Nahrmann, Y., & Johnsen, S. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5412 · Cited by 34
Kawai, T., Morita, K., Masuda, K., Nishida, K., Shikishima, M., Ohta, M., Saito, T., & Rokutan, K. (2007) · Biological Psychology · doi:10.1016/j.biopsycho.2007.07.008 · Cited by 36
Chen, X., Ma, J., Wang, X., Zi, T., Qian, D., Li, C., & Xu, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1106175 · Cited by 39
“Additionally, some studies also reported that patients with a high CCNB1 expression are likely to experience tumour metastasis and have a poor prognosis (27, 28).”
BackgroundBMI1 promotes the progression of laryngeal squamous cell carcinoma
Chen, H., Zhou, L. F., Wan, G., Dou, T., & Tian, J. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.03.016 · Cited by 36
A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells
Dimri, M., Kang, M., & Dimri, G. P. (2016) · Oncotarget · doi:10.18632/oncotarget.8811 · Cited by 38
“In particular, PcG protein BMI1 promotes cancer stem cell (CSC) phenotype and therapy resistance in cancer cells [14, 21].”
BackgroundThe deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators
Kaistha, B. P., Krattenmacher, A., Fredebohm, J., Schmidt, H., Behrens, D., Widder, M., Hackert, T., Strobel, O., Hoheisel, J. D., Gress, T. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19882 · Cited by 37
“Indeed, USP family genes have been proposed as biomarkers in different malignancies [21, 42–45], and further research will have to show if USP5 may be suitable as a novel diagnostic marker and/or novel therapeutic target in pancreatic cancer.”
Regulation of Histone Ubiquitination in Response to DNA Double Strand Breaks
Aquila, L., & Atanassov, B. S. (2020) · Cells · doi:10.3390/cells9071699 · Cited by 39
Prokakis, E., Dyas, A., Grün, R., Fritzsche, S., Bedi, U., Kazerouni, Z. B., Kosinsky, R. L., Johnsen, S. A., & Wegwitz, F. (2021) · Oncogene · doi:10.1038/s41388-021-01814-5 · Cited by 37
The ubiquitin hydrolase USP22 contributes to 3'‐end processing of JAK‐STAT‐inducible genes
Chipumuro, E., & Henriksen, M. A. (2012) · The FASEB Journal · doi:10.1096/fj.11-189498 · Cited by 36
“USP22 is one of the 11 genes identified as the BMI-1 pathway gene signature predictive for aggressive growth, metastasis, and therapeutic resistance (23).”
BackgroundInfluentialDai, S., Xie, C. L., Ding, N., Zhang, Y., Han, L., & Han, Y. (2015) · Medical Oncology · doi:10.1007/s12032-015-0615-x · Cited by 35
“However, there is similarity between gene expression profiles of cancer stem cells and gene expression profiles of metastatic cancer cells [10, 11].”
BackgroundZhou, Y., Chu, P., Wang, Y., Li, N., Gao, Q., Wang, S., Wei, J., Xue, G., Zhao, Y., Jia, H., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado1533 · Cited by 40
“The ubiquitin-specific peptidase 22 (USP22) was initially identified as 1 of the 11 death- from-cancer signature genes that operate a crucial role in regulating tumor cell growth and death ( 9 ).”
Madjd, Z., Ramezani, B., Molanae, S., & Asadi‐Lari, M. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.6.2973 · Cited by 32
“…of Cancer Prevention, Vol 13, 2012 2977 DOI:http://dx.doi.org/10.7314/APJCP.2012.13.6.2973 Expression of Stem Cell Marker ALDH1 in Breast Carcinomas stem cells within breast tumours may correspond to the risk of distant metastases (Abraham et al., 2005; Glinsky et al., 2005; Trimboli et al., 2009).”
BackgroundInfluentialAnjomshoaa, A., Yh, L., Black, M. A., McCall, J. L., Humar, B., Song, S., Fukuzawa, R., Yoon, H.-S., Holzmann, B., Friederichs, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604560 · Cited by 35
Actions of Thyroid Hormone Analogues on Chemokines
Davis, P. J., Glinsky, G. V., Lin, H., & Mousa, S. A. (2016) · Journal of Immunology Research · doi:10.1155/2016/3147671 · Cited by 38
“Microarray gene expression methodology and data analysis pipelines are as previously reported [23, 24].”
Self-citationZhai, R., Tang, F., Gong, J., Zhang, J., Lei, B., Li, B., Wei, Y., Liang, X., Tang, B., & He, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110985 · Cited by 35
“Glinsky et al used genomic technologies to identify the signaling pathways known as “polycomb/cancer stem cell signals” that can predict tumor invasiveness and resistance.(16,17) As members of the polycomb/cancer stem cell signal group, USP22 and BMI1 are activated in many cancer tissues.”
Schmitt, M., Mengele, K., Schüren, E., Sweep, F. C. G. J., Foekens, J. A., Brünner, N., Laabs, J., Malik, A., & Harbeck, N. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.008 · Cited by 34
Yu, W., Jiang, H., Zhang, C., & Yang, P. (2017) · Oncotarget · doi:10.18632/oncotarget.16849 · Cited by 33
Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer
Maynard, M. A., Ferretti, R., Hilgendorf, K. I., Perret, C., Whyte, P., & Lees, J. A. (2013) · Oncogene · doi:10.1038/onc.2013.333 · Cited by 40
Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain
Yadav, A. K., Sahasrabuddhe, A. A., Dimri, M., Bommi, P. V., Sainger, R., & Dimri, G. P. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-158 · Cited by 38
“Consistent with its role in stem cell self-renewal, BMI1 expression is thought to promote stem-ness in tumor cells [12,22], and BMI1 is considered an important marker of breast cancer stem cells [23].”
BackgroundLi, W., Yu, X., Xia, Z., Yu, X., Xie, L., Ma, X., Zhou, H., Liu, L., Wang, J., Yang, Y., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13908 · Cited by 34
Viale, G., Mastropasqua, M. G., Maiorano, E., & Mazzarol, G. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-0103-3 · Cited by 33
“Indeed, the progenitor/ stem cell theory predicts that only some (and possibly a minor percentage of) tumour cells are actually responsible for tumour progression and clinical outcome, and that all efforts should be made to target these cells with specific interventions [16].”
BackgroundSims, A. H., Ong, K. R., Clarke, R. B., & Howell, A. (2006) · Breast Cancer Research · doi:10.1186/bcr1605 · Cited by 35
Xu, H., Liu, Y., Yang, Y., & Dong, X. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1275-8 · Cited by 32
“Increasing experimental evidences suggest that USP22 plays a crucial role in pathological processes of epithelial malignancies and other solid tumors [3].”
BackgroundGlinsky, G. V. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.014 · Cited by 32
“Genome-wide microarray expression profiling experiments revealed that activation of the stemness genomic networks in human malignant tumors is linked with the emergence of clinicallylethal death-from-cancer phenotypes in cancer patients, which are consistently associated with significantly increased likelihood of ther…”
BackgroundResultInfluentialSelf-citationKim, M., Lee, S., Park, W. H., Suh, D. H., Kim, K., Kim, Y. B., & No, J. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.041 · Cited by 32
HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma
Jaeger, M. D. C., Ghisleni, E. C., Cardoso, P. S., Siniglaglia, M., Falcón, T., Brunetto, A. T., Brunetto, A. L., de Farias, C. B., Taylor, M. D., Nör, C., et al. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01505-y · Cited by 32
Conservation and diversity of the eukaryotic SAGA coactivator complex across kingdoms
Chen, Y.-J. C., & Dent, S. (2021) · Epigenetics & Chromatin · doi:10.1186/s13072-021-00402-x · Cited by 36
“A microarray screen identified USP22 as part of the 11-gene “death from cancer” signature driven by B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1), a PRC1 member, in metastatic prostate tumors [111].”
The role of gene expression profiling in early-stage non-small cell lung cancer.
Shao, W., Wang, D., & He, J. (2010) · Europe PMC (PubMed Central) · Cited by 32
Wang, W., Yuasa, T., Tsuchiya, N., Ma, Z., Maita, S., Narita, S., Kumazawa, T., Inoue, T., Tsuruta, H., Horikawa, Y., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24721 · Cited by 32
“Mel-18 is structurally highly similar to Bmi-1, another PcG member whose over-expression has been linked to the highly malignant behavior of various cancer cells including prostate cancer.(5,6) The N-terminal region of Mel-18, which contains a RING finger domain, is 93% homologous to the corresponding region of Bmi-1.”
BackgroundYang, X. H., & Sun, X. S. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-118 · Cited by 33
“In particular, Glinsky and colleagues innovatively published a 11-gene signature that is displayed consistently in stem cells self-renewal pathways, and this is a powerful predictor for prognosis in 11 distinct types of cancer [17].”
BackgroundDo stem-like cells play a role in drug resistance of sarcomas?
Honoki, K. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.184 · Cited by 32
hafez, A. A. E., & El-Hadaad, H. A. (2013) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2013.11.004 · Cited by 33
Polycomb Group Protein Bmi1 Is Required for Growth of RAF Driven Non-Small-Cell Lung Cancer
Becker, M., Korn, C. B., Sienerth, A. R., Voswinckel, R., Luetkenhaus, K., Ceteci, F., & Rapp, U. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004230 · Cited by 32
“recently been identified as a prognostic marker for NSCLC [16,17] and belongs to a group of factors that have been identified as a death-from-cancer signature in human malignancies [18].”
BackgroundPluripotency transcription factors in lung cancer—a review
Sławek-Szmyt, S., Szmyt, K., Fularz, M., Dziudzia, J., Boruczkowski, M., Sikora, J., & Kaczmarek, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4407-x · Cited by 31
Bastian, L., Hartmann, A., Beder, T., Hänzelmann, S., Kässens, J. C., Bultmann, M., Hoeppner, M. P., Franzenburg, S., Wittig, M., Franke, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01557-6 · Cited by 31
“It is essential for activation of the SAGA histone deubiquitinase module (DUBm) through USP22, which is part of the 11-gene signature “Death-from-cancer” [6] defining poor outcomes across entities.”
BackgroundPotent macrocycle inhibitors of the human SAGA deubiquitinating module
Morgan, M. T., Ikenoue, T., Suga, H., & Wolberger, C. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.12.004 · Cited by 34
Glinsky, G. V. (2008) · Cell Cycle · doi:10.4161/cc.7.23.7153 · Cited by 34
Self-citationGlinskii, A. B., Ma, S., Ma, J., Grant, D., Lim, C., Guest, I., Sell, S., Buttyan, R., & Glinsky, G. V. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17842 · Cited by 35
“hTERTimmortalized BJ1, LNCap, and LNCapLN3 cells were previously described (38-42).”
BackgroundMethodInfluentialSelf-citationBaxter, P. A., Qi, L., Mao, H., Kogiso, M., Zhao, X., Liu, Z., Huang, Y., Voicu, H., Gurusiddappa, S., Su, J. M. F., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0160-4 · Cited by 32
Schade, B., Lam, S. H. L., Cernea, D. D., Sanguin‐Gendreau, V., Cardiff, R. D., Jung, B. L., Hallett, M. T., & Muller, W. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4724 · Cited by 34
BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation
Wei, F., Ojo, D., Lin, X., Wong, N., He, L., Yan, J., Xu, S., Major, P. P., & Tang, D. (2014) · Oncogene · doi:10.1038/onc.2014.235 · Cited by 36
Spolverini, A., Fuchs, G., Bublik, D. R., & Oren, M. (2017) · Oncogene · doi:10.1038/onc.2017.187 · Cited by 33
MicroRNAs, a Promising Target for Breast Cancer Stem Cells
Das, P. K., Siddika, M. A., Asha, S. Y., Aktar, S., Rakib, M. A., Khanam, J. A., Pillai, S., & Islam, F. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00439-5 · Cited by 30
Yong, A. S. M., Stephens, N., Weber, G., Yixin, L. I., Savani, B. N., Eniafe, R. B., Keyvanfar, K., Kurlander, R. J., Rezvani, K., & Barrett, A. J. (2011) · Leukemia · doi:10.1038/leu.2010.325 · Cited by 31
“A high expression of BMI-1 in solid tumors(12) and leukemias(10, 13, 14) is associated with more rapid disease progression and poor outcome, implying that an increased level of stem-ness conferred by BMI-1 contributes to leukemogenicity and refractoriness to conventional cytotoxic treatment(3).”
The potential role of O-GlcNAc modification in cancer epigenetics
Forma, E., Jóźwiak, P., Bryś, M., & Krześlak, A. (2014) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-014-0204-6 · Cited by 37
“HCF-1 is overexpressed in cancers and this is one of the markers of a poor prognosis in cancer treatment [83].”
BackgroundHistone H2B ubiquitination: signaling not scrapping
Bonnet, J., Devys, D., & Tora, L. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.09.002 · Cited by 43
Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation
Ricke, R. M., & van Deursen, J. M. (2011) · Cell Cycle · doi:10.4161/cc.10.21.18156 · Cited by 38
TCEB1 promotes invasion of prostate cancer cells
Jalava, S. E., Porkka, K. P., Rauhala, H. E., Isotalo, J., Tammela, T. L. J., & Visakorpi, T. (2008) · International Journal of Cancer · doi:10.1002/ijc.23916 · Cited by 30
“Decreased expression of ANK3 was associated with good prognosis phenotype.(29) Another extracellular matrix component, CHRDL2, also known as BNF-1, is found to be upregulated in tumors.”
BackgroundGene Expression With Prognostic Implications in Cytogenetically Normal Acute Myeloid Leukemia
Baldus, C. D., & Bullinger, L. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.006 · Cited by 33
USP22 controls iNKT immunity through MED1 suppression of histone H2A monoubiquitination
Zhang, Y., Wang, Y., Gao, B., Sun, Y., Cao, L., Genardi, S., Wang, C.-R., Li, H., Sun, Z., Yang, Y., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182218 · Cited by 31
“Ubiquitin-specific peptidase 22 (USP22) was initially identified as a death from signature genes involved in cancer development, metastasis, and chemotherapy resistance (Glinsky et al., 2005).”
BackgroundConsensus genes of the literature to predict breast cancer recurrence
Lauss, M., Kriegner, A., Vierlinger, K., Visne, I., Yildiz, A., Dilaveroǧlu, E., & Noehammer, C. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9716-3 · Cited by 34
“Additionally we added some selected studies that are indirectly related to breast cancer prognosis, resulting in a total of 44 gene lists from 42 studies [3–6, 13, 16, 20–55] (Supplementary Table 1, online).”
BackgroundWang, T., Abou–Ouf, H., Hegazy, S. A., Alshalalfa, M., Stoletov, K. V., Lewis, J. D., Donnelly, B. J., & Bismar, T. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1458-4 · Cited by 32
“To our knowledge, we are aware of only one previous study which reported that downregulation of the ANK3 correlates with poor prognosis in diverse human tumors such as breast, prostate, lung, and ovarian cancers [16].”
Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies
Cicirò, Y., Ragusa, D., & Sala, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-55080-y · Cited by 31
“Nevertheless, variability in expression patterns is known in the literature, including subtype-specific up-or downregulation of BUB1 compared to normal tissue 24,26–28 , 83– 85 .”
BackgroundOjo, D., Lin, X.-Z., Wu, Y., Cockburn, J., Bane, A., & Tang, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.048 · Cited by 22
Антонова, А. В., Hummel, B., Khavaran, A., Redhaber, D. M., Aprile-Garcia, F., Rawat, P., Gundel, K., Schneck, M., Hansen, E. C., Mitschke, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.084 · Cited by 29
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
Maroni, G., Bassal, M. A., Krishnan, I., Fhu, C. W., Savova, V., Žilionis, R., Maymi, V. A., Pandell, N., Csizmadia, E., Zhang, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01897-6 · Cited by 29
Sun, T., Zhang, K., Li, W., Liu, Y., Pangeni, R. P., Li, A., Arvanitis, L. D., & Raz, D. J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00946-9 · Cited by 30
“USP22 is also considered a putative cancer stem cells (CSCs) marker in varous cancers [4, 8], while CSCs are known for therapy resistance and recurrence in cancers.”
Promising tumor‐associated antigens for future prostate cancer therapy
Li, Y., Cozzi, P. J., & Russell, P. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20165 · Cited by 32
“Prostate CSCs also display a unique gene expression signature that can be related to Gleason grade and patient outcome.(202) However, several properties of human CaPs suggest that the disease may instead arise from a PSC (such as in Fig.”
Bmi‐1 is critical for the proliferation and invasiveness of gastric carcinoma cells
Li, W., Li, Y., Tan, Y., Ma, K., & Cui, J. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06045.x · Cited by 28
Clinical Uses of Microarrays in Cancer Research
Virtanen, C., & Woodgett, J. R. (2008) · Methods in molecular medicine · doi:10.1007/978-1-60327-148-6_6 · Cited by 32
“C IH R A uthor M anuscript C IH R A uthor M anuscript C IH R A uthor M anuscript study, Glinsky et al (23) combined data from mouse and human prostate tumor samples to derive an 11 gene signature that consistently holds a stem-cell type expression profile predicting poor outcome across a variety of cancer types.”
BackgroundBartucci, M., Hussein, M. S., Huselid, E., Flaherty, K., Patrizii, M., Laddha, S. V., Kui, C., Bigos, R. A., Gilleran, J., El‐Ansary, M., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0501-x · Cited by 28
Vora, P., Seyfrid, M., Venugopal, C., Qazi, M. A., Salim, S. K., Isserlin, R., Subapanditha, M., O’Farrell, E., Mahendram, S., Singh, M., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03192-1 · Cited by 29
Targeted therapy against cancer stem cells
Yang, T., & Rycaj, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3172 · Cited by 29
“BMI-1 expression has been associated with aggressive colon cancer and poor patient outcome, and also mediates chemotherapy and radiation resistance (50).”
BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer
Zhu, S. L., Zhao, D., Li, C., Li, Q., Jiang, W., Liu, Q., Wang, R., Fazli, L., Li, Y., Zhang, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0966-4 · Cited by 27
USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis
Li, M., Xu, Y., Liang, J., Lin, H. R., Qi, X., Li, F., Han, P., Gao, Y., & Yang, X. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.018 · Cited by 31
Gene expression identifies heterogeneity of metastatic propensity in high‐grade soft tissue sarcomas
Skubitz, K. M., Francis, P., Skubitz, A. P. N., Luo, X., & Nilbert, M. C. (2012) · Cancer · doi:10.1002/cncr.26733 · Cited by 28
Targeting Head and Neck Cancer Stem Cells: Current Advances and Future Challenges
Birkeland, A. C., Owen, J. H. J., & Prince, M. E. (2015) · Journal of Dental Research · doi:10.1177/0022034515601960 · Cited by 28
Fucito, A., Lucchetti, C., Giordano, A., & Romano, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.018 · Cited by 38
Zhang, F., Song, X., Li, L., Wang, J., Lin, L., Li, C., Li, H., Lv, Y., Jin, Y., Liu, Y., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2921-x · Cited by 27
“Polycomb protein BMI-1 is broadly overexpressed in various types of cancer cells, such as leukemia [1], mantle cell lymphoma [2], non-small-cell lung cancer [3], breast cancer [4], colorectal cancer [5], nasopharyngeal carcinoma [6], prostate cancer [7], and ovarian cancer [8], and its depletion in those cells often l…”
BackgroundUpdate: Molecular Imaging and Personalized Medicine: An Uncertain Future
Nunn, A. D. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.0417 · Cited by 27
Siddique, H. R., Parray, A., Zhong, W., Karnes, R. J., Bergstralh, E. J., Koochekpour, S., Rhim, J. S., Konety, B. R., & Saleem, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052993 · Cited by 27
“[18] previously showed that Bmi1 protein is elevated in the prostatic tissues of TRAMP mice, an autochthonous mouse model of CaP development, we investigated if a progressive increase in the levels of Bmi1 in prostatic tissues could be detected during progressive age of CaP.”
BackgroundGergely, J. E., Dorsey, A. E., Dimri, G. P., & Dimri, M. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22804 · Cited by 29
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.